Clinical Trial Update: Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) [Phase 3]

View source ↗

Summary

Phase 3 study results update for Doravirine (MK-1439) in HIV-1 infection, reporting safety and efficacy data with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Doravirine (doravirine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 | Phase 3 | Status: COMPLETED | Results posted: 2018-10-23